NEWBURGH, Ind (WEHT) – Researchers at Indiana University say they have made a breakthrough in predicting and treating breast cancer, and some of that research was done in the Tri-State.
For more than four years, Indiana University researchers have studied ways to detect possible signs of remaining triple-negative breast cancer material before a relapse.
Triple-negative breast cancer is one of the most aggressive and deadliest types of breast cancer because it lacks common traits used to diagnose and treat most other breast cancers.
Some of that research was conducted at Oncology Hematology Associates of southwest Indiana in Newburgh.
Doctor Bryan Schneider is the co-leader of the research project. He says 90% of patients who went through chemotherapy and surgery were cured.
“Conversely, the other two-thirds that have residual disease removed at the time of surgery have a much higher risk of relapsing, so about half of these patients will have recurrence,” said Dr. Schneider.
During the study, researchers used innovative technology to take a simple blood sample along with special techniques to detect a tumor cell.
90% of those without it were found to remain cancer-free after two years.
“For me, I’m very hopeful for the future and continuing my survivorship without a recurrence because this lays a foundation for more trials, more interventions, and more therapies so that individuals can be hopeful just their life,” says triple-negative breast cancer survivor, Nadia E. Miller.
(This story was originally published on December 13, 2019)
Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.